Compare Huntington Ingalls Industries Inc (HII) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

HII trades at $264.51, up 1.47% with a bearish technical signal despite recent earnings beats. The company shows solid fundamentals with a $12.48B revenue, 5.01% net margin, and attractive valuation (P/E 15.78, P/S 0.79). Recent contract wins including a $5.1B aircraft carrier overhaul and 10 unmanned vessel orders provide strong revenue visibility. Analyst consensus is mixed with 40.7% buy ratings but a $363.67 price target suggesting 37% upside potential.

The stock presents value opportunity with strong defense sector positioning and $57.3B backlog, though technical weakness and execution risks on major contracts warrant caution. Upside catalysts include continued earnings beats and contract execution, while risks involve defense budget uncertainty and project delays. Current levels offer entry point for long-term investors given the significant discount to analyst targets.

INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.

The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.